716 related articles for article (PubMed ID: 23446337)
1. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
Varma P; Paul E; Huang C; Headon B; Sparrow MP
Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
5. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
Patil SA; Rustgi A; Langenberg P; Cross RK
Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
[TBL] [Abstract][Full Text] [Related]
10. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
11. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
13. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
[TBL] [Abstract][Full Text] [Related]
14. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
16. Experience with anti-TNF-α therapy for orofacial granulomatosis.
Elliott T; Campbell H; Escudier M; Poate T; Nunes C; Lomer M; Mentzer A; Patel P; Shirlaw P; Brostoff J; Challacombe S; Sanderson J
J Oral Pathol Med; 2011 Jan; 40(1):14-9. PubMed ID: 21249727
[TBL] [Abstract][Full Text] [Related]
17. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
19. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
